Research Analysts Issue Forecasts for LRMR FY2025 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities researchers at HC Wainwright dropped their FY2025 earnings per share estimates for Larimar Therapeutics in a research report issued to clients and investors on Tuesday, March 25th. HC Wainwright analyst E. White now forecasts that the company will earn ($1.91) per share for the year, down from their prior estimate of ($1.77). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($2.10) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last announced its earnings results on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

A number of other research firms also recently commented on LRMR. Guggenheim reaffirmed a “buy” rating and set a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday. Truist Financial assumed coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Robert W. Baird cut their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $20.22.

Larimar Therapeutics Stock Down 2.1 %

Shares of NASDAQ:LRMR opened at $2.35 on Thursday. The stock has a market cap of $149.95 million, a P/E ratio of -2.04 and a beta of 0.99. The business’s 50 day moving average is $3.08 and its 200 day moving average is $5.12. Larimar Therapeutics has a 52-week low of $2.19 and a 52-week high of $11.20.

Institutional Investors Weigh In On Larimar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LRMR. BNP Paribas Financial Markets purchased a new position in Larimar Therapeutics during the fourth quarter valued at $25,000. Quest Partners LLC raised its position in shares of Larimar Therapeutics by 171.1% during the 3rd quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock worth $60,000 after purchasing an additional 5,796 shares during the last quarter. Virtu Financial LLC purchased a new position in Larimar Therapeutics in the 3rd quarter valued at about $71,000. Quarry LP boosted its holdings in Larimar Therapeutics by 50.0% in the 3rd quarter. Quarry LP now owns 12,000 shares of the company’s stock worth $79,000 after buying an additional 4,000 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in Larimar Therapeutics in the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.